Page last updated: 2024-12-05

2-chlorobenzaldehyde

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-Chlorobenzaldehyde is an organic compound with the formula C7H5ClO. It is a colorless liquid with a pungent odor. It is used as an intermediate in the synthesis of various organic compounds, including pharmaceuticals, pesticides, and dyes. 2-Chlorobenzaldehyde is also used as a flavoring agent and fragrance ingredient. It is known to be an irritant to the skin, eyes, and respiratory system. The compound is studied for its potential applications in the synthesis of other important chemicals, as well as its biological activity. Its chemical structure allows it to react with various reagents, opening up possibilities for the development of new compounds.'

Cross-References

ID SourceID
PubMed CID6996
CHEMBL ID1547989
SCHEMBL ID97422
MeSH IDM0165131

Synonyms (74)

Synonym
benzaldehyde, o-chloro-
2-chlorobenzaldehyde
usaf m-7
nsc-15347
89-98-5
nsc15347
2-chlorbenzaldehyd
o-chloorbenzaldehyde
o-chlorobenzaldehyde
wln: vhr bg
benzaldehyde, 2-chloro-
2-chloorbenzaldehyde
2-clorobenzaldeide
inchi=1/c7h5clo/c8-7-4-2-1-3-6(7)5-9/h1-5
NCGC00091218-01
ccris 5991
o-chlorobenzenecarboxaldehyde
hsdb 2727
2-clorobenzaldeide [italian]
2-chlorbenzaldehyd [german]
o-chloorbenzaldehyde [dutch]
einecs 201-956-3
2-chloorbenzaldehyde [dutch]
ai3-04254
nsc 15347
35913-09-8
benzaldehyde, chloro-
chlorobenzaldehyde
2-chlorobenzaldehyde, 99%
MLS001056242
smr001216556
FT-0658390
AKOS000119188
NCGC00091218-02
2-chloro-benzaldehyde
cas-89-98-5
NCGC00257927-01
dtxcid204764
dtxsid5024764 ,
tox21_200373
nsc 174140
STL146016
ec 201-956-3
unii-qhr24x1lxk
qhr24x1lxk ,
FT-0611909
FT-0611908
chlorobenzaldehyde, o-
SCHEMBL97422
(2-chloro) benzaldehyde
2-chlorobezaldehyde
2-chlorobenzenaldehyde
2-chloro benzaldehyde
(2-chloro)benzaldehye
6-chlorobenzaldehyde
(2-chloro)benzaldehyde
2- chlorobenzaldehyde
o-chlorobezaldehyde
o-chloroformylbenzene
W-100351
STR00143
CHEMBL1547989
benzaldehyde,chloro-
F2190-0599
mfcd00003304
2-chlorobenzaldehyde, purum, dist., >=98.0% (gc)
CS-W003973
Q2195231
EN300-19123
AMY39073
D77644
orthochlorobenzaldehyde
ortho-chlorobenzaldehyde
Z104472866
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.02240.000214.376460.0339AID588532
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency39.49780.003041.611522,387.1992AID1159552; AID1159555
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1544945Inhibition of NO711 binding to mouse GAT1 expressed in HEK293 cell membranes assessed as residual binding at 1 uM incubated for 4 hrs in presence of NO711 by LC-ESI-MS/MS analysis relative to control2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Application of the concept of oxime library screening by mass spectrometry (MS) binding assays to pyrrolidine-3-carboxylic acid derivatives as potential inhibitors of γ-aminobutyric acid transporter 1 (GAT1).
AID1127995Toxicity in Staphylococcus aureus ATCC 25923 after 24 hrs by microdilution method2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.
AID1337095Inhibition of human MPO2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
From Dynamic Combinatorial Chemistry to
AID1127996Toxicity in fluoroquinolone-resistant Staphylococcus aureus 1199B expressing NorA after 24 hrs by microdilution method2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.
AID1127992Inhibition of NorA in fluoroquinolone-resistant Staphylococcus aureus 1199B assessed as potentiation of 4 ug/ml of ciprofloxacin MIC at 100 ug/ml after 24 hrs by microdilution method2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (9.09)18.7374
1990's1 (9.09)18.2507
2000's3 (27.27)29.6817
2010's6 (54.55)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.12 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index66.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]